Benta Pharma Industries

What Benta Pharma Industries does

Benta Pharma Industries (BPI) is a Lebanon-based pharmaceutical manufacturer and subsidiary of the Benta Group conglomerate, founded in 2005/2006 and headquartered in Dbayeh, Lebanon. The company manufactures generic pharmaceutical products and medical devices across 10+ therapeutic areas including cardiovascular, central nervous system, diabetes, dermatology, urology, transplant, anesthesia, oncology, biotech, and sterile products. BPI operates two cGMP-certified manufacturing facilities — its primary site in Dbayeh, Lebanon and a second site in Saint-Genis-Laval (Lyon), France acquired in July 2020 from Famar and rebranded as Benta Lyon — and produces a portfolio of 200+ products distributed to 40+ countries.

BPI's business model is B2B manufacturing: products are sold through direct relationships with regional pharmaceutical distributors, healthcare providers, hospitals, and pharmacies. Pricing is contract-based and not publicly disclosed. The company has demonstrated first-to-market generic capability with the February 2021 launch of RIXALTA, the first generic Rivaroxaban (an oral anticoagulant) in the market. The company employs 250+ staff across its two manufacturing sites and pursues international expansion through participation in major pharmaceutical trade events including CPhI Worldwide (Frankfurt 2022, Barcelona 2023) and the Made In Lebanon Exhibition (2024). BPI is led by CEO Bernard Tannoury and is privately held under the Benta Group umbrella with no external institutional investment or public listing identified.

Name

Benta Pharma Industries

Legal name

Benta Pharma Industries

Website

https://bpi.com.lb

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

101–250 employees

Short description

Benta Pharma Industries is a Lebanon-headquartered generic pharmaceutical and medical device manufacturer operating two cGMP facilities (Lebanon and France). The company produces 200+ products across 10+ therapeutic areas for B2B distribution to healthcare providers and pharmaceutical distributors in 40+ countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals manufacturing
• Medical device production
• Enhanced formulation drugs
• Sterile pharmaceutical products
• CGMP certified manufacturing

Headquarters

HQ city

Dbayeh

HQ country

Lebanon

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Products Manufacturing: Manufacturing and sale of generic pharmaceutical products including cardiovascular, CNS, diabetes, dermatology, urology, transplant, and anesthesia treatments
2. Generic Drug Production: First-to-market generic drug launches such as RIXALTA (Rivaroxaban generic)
3. Medical Devices: Manufacturing and sale of medical devices

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Benta Pharma Industries manufactures generic pharmaceutical products and medical devices at two cGMP-certified facilities in Lebanon and France. Its portfolio covers enhanced formulations for cardiovascular, central nervous system, diabetes, dermatology, urology, transplant, anesthesia, oncology, biotech, and sterile products, and includes first-to-market generics such as RIXALTA® (the first Rivaroxaban generic). Products are sold B2B to distributors, hospitals, pharmacies, and healthcare systems across 40+ countries.

Product overview

Benta Pharma Industries (BPI) is a pharmaceutical manufacturing company that produces high-quality pharmaceutical products and medical devices. The company manufactures enhanced formulations for treating a variety of diseases including cardiovascular conditions, central nervous system disorders, diabetes, dermatology, urology, transplant, anesthesia, oncology, biotech, and sterile products. The product portfolio includes 200 products distributed across 40 countries, with key products such as RIXALTA® (the first Rivaroxaban generic). The company operates 2 cGMP-certified manufacturing facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• RIXALTA® RIXALTA® is Benta Pharma Industries' first-to-market generic version of Rivaroxaban, an anticoagulant medication used to prevent and treat blood clots. It is sold B2B to pharmaceutical distributors, hospitals, and pharmacies across the markets where BPI is registered.
• Generic Pharmaceutical Product Portfolio Benta Pharma Industries manufactures a portfolio of 200+ generic pharmaceutical products across multiple therapeutic categories, including cardiovascular disease treatments, central nervous system medications, diabetes therapies, dermatological products, urology treatments, transplant-support medications, anesthesia products, oncology, biotech, and sterile products. These are produced at the cGMP-certified facilities in Lebanon and France and sold B2B to distributors, hospitals, and pharmacies in 40+ countries.
• Medical Devices Benta Pharma Industries manufactures medical devices alongside its pharmaceutical products, supplying healthcare providers and distributors. Medical device production is integrated into the company's operations at its cGMP-certified facilities.

Quantifiable outcome

• Products distributed to 40 countries
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Benta GroupcoreOthersBenta Pharma Industries is a subsidiary and core operating company of Benta Group, a Lebanese conglomerate with pharmaceutical and healthcare operations. BPI operates as the group's pharmaceutical manufacturing division.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Julphar (Gulf Pharmaceutical Industries): MENA-headquartered generic pharmaceutical manufacturer producing generic drugs, OTC products, and medical devices across multiple therapeutic categories for regional and emerging markets — directly comparable to BPI in business model, therapeutic breadth, and geographic footprint.
• Tabuk Pharmaceuticals: Saudi-headquartered generic and specialty pharmaceutical manufacturer with manufacturing across multiple dosage forms and distribution across MENA markets — comparable to BPI in scale, product breadth, and emerging-market focus.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances): Saudi pharmaceutical manufacturer producing generics, branded drugs, and medical appliances across MENA — directly comparable to BPI's combined pharmaceutical + medical device manufacturing business.
• Acdima (Arab Company for Drug Industries and Medical Appliances): Jordan-based pharmaceutical and medical appliance manufacturer serving MENA and emerging markets with generic drugs across multiple therapeutic areas — closely aligned with BPI's regional scope and product mix.

Broad incumbents

• Hikma Pharmaceuticals: Jordan-headquartered global generic and specialty pharmaceutical company with manufacturing in MENA, US, and Europe — a much larger incumbent competing with BPI in generic injectables, oral solids, and branded generics across overlapping markets.
• Cipla: Indian-headquartered global pharmaceutical manufacturer with leading positions in generics, complex APIs, and emerging-market distribution — overlapping with BPI in generic portfolio breadth and emerging-market export orientation.
• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with diversified dosage forms and global export reach across 150+ countries — comparable to BPI in manufacturing footprint strategy and generic therapeutic breadth, though materially larger.
• Teva Pharmaceutical Industries: Israeli-headquartered global leader in generic pharmaceuticals with broad specialty and complex generic portfolio — competes with BPI in the same generic molecule categories and increasingly in emerging markets where BPI is active.

Emerging players

• Aspen Pharmacare: South African-headquartered specialty and generic pharmaceutical group with manufacturing in Africa, Europe, and Australasia — comparable emerging-market generic manufacturer with similar international expansion strategy to BPI.

Regional players

• Pharma 5: Moroccan generic pharmaceutical manufacturer producing generics across multiple therapeutic categories for North and West African markets — a regional peer with similar product mix and emerging-market positioning as BPI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/BPI_tweets
• Facebookfacebook.com/BentaPharmaIndustries
• LinkedInlinkedin.com/company/benta-pharma-industries--bpi

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Benta Pharma Industries